Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

Table 3 Univariate and multivariate analysis by subgroup for time under treatment

	Univariate analysis				Multivariate analysis
	HR	95%CI		P vaule	HR	95%CI		P vaule
Tumor location				0.1204				0.4288
CR	Ref				Ref
Pancréas	1.615	0.882	2.958		1.316	0.667	2.599
Metastatic sites				0.0478				0.1405
0-1	Ref				Ref
≥ 2	0.56	0.315	0.994		0.613	0.32	1.175
Age				0.2105				0.1637
< 75	Ref				Ref
≥ 75	0.692	0.389	1.231		0.664	0.373	1.182
Age				0.371
< 80	Ref
≥ 80	1.394	0.673	2.889
Comorbidities				0.979
No	Ref
Yes	1.008	0.549	1.851
Neoadjuvant chemotherapy				0.2339
No	Ref
Yes	2.432	0.563	10.5
Initial autonomy (J0)				0.9059
No	Ref
Yes	0.932	0.288	3.018
Charlson comorbidities index				0.7659
< 10	Ref
≥ 10	0.915	0.511	1.639
ECOG performance status				0.5046
0-1	Ref
≥ 2	1.281	0.618	2.655
Sexe				0.7228
Male	Ref
Female	0.856	0.361	2.026
Number of usual drugs				0.3057
< 4	Ref
≥ 4	1.34	0.765	2.347